Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 4 September 1970:
Vol. 169. no. 3949, pp. 987 - 989
DOI: 10.1126/science.169.3949.987
Prev | Table of Contents | Next

Articles

Enzyme Replacement in Fabry's Disease, an Inborn Error of Metabolism

Carol A. Mapes 1, Richard L. Anderson 1, Charles C. Sweeley 1, Robert J. Desnick 2, and William Krivit 2

1 Department of Biochemistry, Michigan State University, East Lansing 48823
2 Dight Institute for Human Genetics and Department of Pediatrics, University of Minnesota Medical School, Minneapolis

Two patients with Fabry's disease were infused with normal plasma to provide active enzyme (ceramide trihexosidase) for hydrolysis of the plasma substrate, galactosylgalactosylglucosylceramide. Maximum ceramide trihexosidase activity occurred 6 hours after infusion of the plasma, attaining a level approximately 150 percent of that in normal plasma; enzymatic activity was detectable for 7 days. The amount of accumulated substrate in the plasma of these recipients decreased about 50 percent on day 10 after infusion. Thus, periodic replacement of ceramide trihexosidase activity in the plasma of patients with Fabry's disease might lead to consistently lower amounts of substrate in the plasma and a decrease in its rate of accumulation in tissues.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.
K. Lee, X. Jin, K. Zhang, L. Copertino, L. Andrews, J. Baker-Malcolm, L. Geagan, H. Qiu, K. Seiger, D. Barngrover, et al. (2003)
Glycobiology 13, 305-313
   Abstract »    Full Text »    PDF »
Safety and Efficacy of Recombinant Human {alpha}-Galactosidase A Replacement Therapy in Fabry's Disease.
C. M. Eng, N. Guffon, W. R. Wilcox, D. P. Germain, P. Lee, S. Waldek, L. Caplan, G. E. Linthorst, R. J. Desnick, and the International Collaborative Fabry Disease Stud (2001)
N. Engl. J. Med. 345, 9-16
   Abstract »    Full Text »    PDF »
New Therapies for Fabry's Disease.
W. A. Gahl (2001)
N. Engl. J. Med. 345, 55-57
   Full Text »    PDF »
Failure to Correct the Metabolic Defect by Renal Allotransplantation in Fabry's Disease.
M. W. SPENCE, K. E. MacKINNON, J. K. BURGESS, D. M. d'ENTREMONT, P. BELITSKY, S. G. LANNON, and A. S. MacDONALD (1976)
Ann Intern Med 84, 13-16
   Abstract »    PDF »
The Treatment of Genetic Disorders.
S. A. Muller (1975)
Arch Dermatol 111, 1620-1624
   Abstract »    PDF »
Antenatal Diagnosis and Therapeutic Trends in Sphingolipidoses.
L. Schneck, D. Amsterdam, and B. W. Volk (1974)
JAMA 228, 615-618
   Abstract »    PDF »
A Kidney Transplant Patient With Fabry's Disease: Unusual Features.
J. Suros, J. E. Woods, C. F. Anderson, P. P. Frohnert, F. J. Kazmier, K. E. Holley, F. C. Riley, and J. H. DeWeerd (1973)
Arch Surg 106, 231-233
   Abstract »    PDF »
Implantation of Exogenous Enzymatic Activity in Isolated Alveolar Macrophages.
J. Theodore, J. C. Acevedo, and E. D. Robin (1972)
Science 178, 1302-1304
   Abstract »    PDF »
SONORAN DERMATOLOGICAL SOCIETY.
W. E. Carson (1972)
Arch Dermatol 106, 589-590
   Abstract »    PDF »
Reversal of an Inborn Sphingolipidosis (Fabry's Disease) by Kidney Transplantation.
M. PHILIPPART, S. S. FRANKLIN, and A. GORDON (1972)
Ann Intern Med 77, 195-200
   Abstract »    PDF »
Allotransplantation for the Treatment of Inborn Errors of Metabolism.
H. L. NADLER (1972)
Ann Intern Med 77, 314-316
   Abstract »    PDF »
Gene Therapy for Human Genetic Disease?.
T. Friedmann and R. Roblin (1972)
Science 175, 949-955
   Abstract »    PDF »
Macular Cherry-Red Spot, Corneal Clouding, and {beta}-Galactosidase Deficiency: Clinical, Biochemical, and Electron Microscopic Study of a New Autosomal Recessive Storage Disease.
M. F. Goldberg, E. Cotlier, L. G. Fichenscher, K. Kenyon, R. Enat, and S. A. Borowsky (1971)
Arch Intern Med 128, 387-398
   Abstract »    PDF »
Correction of Abnormal Cerebroside Sulfate Metabolism in Cultured Metachromatic Leukodystrophy Fibroblasts.
M. T. Porter, A. L. Fluharty, and H. Kihara (1971)
Science 172, 1263-1265
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)